EGFR and non-small cell lung carcinoma: The success of this trial led to osimertinib being prioritized in the National Comprehensive Cancer Network (NCCN) guidelines in 2019 as a first-line treatment for metastatic EGFR-mutated NSCLC [8,9,10,11,12].